S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$9.94
$3.49
$10.30
$579.72M2.311.43 million shs1.66 million shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.16
$1.15
$0.98
$1.89
$36.26M-0.6866,353 shs2,220 shs
CVRx, Inc. stock logo
CVRX
CVRx
$15.45
+1.2%
$19.95
$9.07
$33.13
$333.57M1.29143,732 shs12,753 shs
DarioHealth Corp. stock logo
DRIO
DarioHealth
$1.16
+0.8%
$1.68
$0.68
$4.58
$34.14M1.66135,473 shs11,124 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$14.12
+0.9%
$14.53
$3.80
$18.15
$371.07M2.08105,179 shs12,861 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
0.00%0.00%0.00%0.00%0.00%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
+1.75%-6.45%+5.45%-4.92%-22.15%
CVRx, Inc. stock logo
CVRX
CVRx
-2.86%-15.64%-26.17%-42.48%+61.31%
DarioHealth Corp. stock logo
DRIO
DarioHealth
-4.96%-20.42%-19.58%-50.00%-67.97%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
+1.82%-3.48%+4.09%-2.03%+194.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.7326 of 5 stars
3.02.00.04.40.60.00.6
CVRx, Inc. stock logo
CVRX
CVRx
2.4011 of 5 stars
3.51.00.00.03.23.30.6
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.2344 of 5 stars
3.52.00.00.00.00.81.3
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.4315 of 5 stars
3.43.00.00.01.84.20.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50115.52% Upside
CVRx, Inc. stock logo
CVRX
CVRx
3.00
Buy$33.67117.91% Upside
DarioHealth Corp. stock logo
DRIO
DarioHealth
3.00
Buy$5.37362.84% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.86
Moderate Buy$15.6710.95% Upside

Current Analyst Ratings

Latest DRIO, NPCE, APEN, CVRX, and CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
DarioHealth Corp. stock logo
DRIO
DarioHealth
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
3/14/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $13.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00
2/22/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $16.00
1/30/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/30/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
1/26/2024
CVRx, Inc. stock logo
CVRX
CVRx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$21.00 ➝ $33.00
1/26/2024
CVRx, Inc. stock logo
CVRX
CVRx
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$76.86M0.00N/AN/A$0.69 per share0.00
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.32N/AN/A$2.81 per share0.41
CVRx, Inc. stock logo
CVRX
CVRx
$39.29M8.49N/AN/A$3.65 per share4.23
DarioHealth Corp. stock logo
DRIO
DarioHealth
$20.35M1.68N/AN/A$2.14 per share0.54
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$65.42M5.67N/AN/A$0.79 per share17.87

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
CVRx, Inc. stock logo
CVRX
CVRx
-$41.20M-$1.98N/AN/AN/A-104.85%-47.30%-35.88%4/30/2024 (Confirmed)
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$59.43M-$1.03N/AN/AN/A-165.96%-48.84%-31.56%5/9/2024 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$32.96M-$1.28N/AN/AN/A-50.38%-153.76%-31.73%5/8/2024 (Confirmed)

Latest DRIO, NPCE, APEN, CVRX, and CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.32N/A+$0.32N/AN/AN/A  
4/30/2024N/A
CVRx, Inc. stock logo
CVRX
CVRx
-$0.53N/A+$0.53N/AN/AN/A  
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/5/2024Q4 2023
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.33-$0.23+$0.10-$0.23$17.74 million$18.01 million    
1/25/2024Q4 2023
CVRx, Inc. stock logo
CVRX
CVRx
-$0.55-$0.44+$0.11-$0.44$10.90 million$11.31 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
CVRx, Inc. stock logo
CVRX
CVRx
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
1.04
2.35
1.89
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
CVRx, Inc. stock logo
CVRX
CVRx
0.38
14.25
12.86
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.42
3.79
3.38
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.76
5.71
5.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
76.01%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
CVRx, Inc. stock logo
CVRX
CVRx
75.27%
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%

Insider Ownership

CompanyInsider Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
17.30%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
CVRx, Inc. stock logo
CVRX
CVRx
18.30%
DarioHealth Corp. stock logo
DRIO
DarioHealth
10.10%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
27.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
20257.97 million47.94 millionNot Optionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
CVRx, Inc. stock logo
CVRX
CVRx
20021.59 million17.64 millionOptionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
27629.44 million26.47 millionOptionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17126.28 million19.06 millionOptionable

DRIO, NPCE, APEN, CVRX, and CODX Headlines

SourceHeadline
Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of StockInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of Stock
insidertrades.com - April 19 at 6:53 AM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in Stock
marketbeat.com - April 18 at 6:51 PM
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
globenewswire.com - April 17 at 4:05 PM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 SharesNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 Shares
americanbankingnews.com - April 16 at 4:18 AM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in Stock
insidertrades.com - April 16 at 4:17 AM
Orbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOrbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock
marketbeat.com - April 15 at 6:47 PM
Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)
americanbankingnews.com - April 15 at 2:00 AM
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 14 at 4:08 AM
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from BrokeragesNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages
marketbeat.com - April 14 at 4:07 AM
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%
marketbeat.com - April 12 at 12:14 AM
NeuroPace (NASDAQ: NPCE)NeuroPace (NASDAQ: NPCE)
fool.com - April 10 at 3:47 PM
Kent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)Kent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)
marketbeat.com - April 6 at 7:28 PM
Biggest mistake bond investors may make ahead of Fed rate cuts'Biggest mistake' bond investors may make ahead of Fed rate cuts
msn.com - April 4 at 7:38 PM
NeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceNeuroPace to Present at the Needham 23rd Annual Healthcare Conference
globenewswire.com - March 27 at 4:05 PM
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
marketbeat.com - March 20 at 5:13 AM
The Latest Analyst Ratings For NeuroPaceThe Latest Analyst Ratings For NeuroPace
markets.businessinsider.com - March 13 at 5:40 AM
NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers
markets.businessinsider.com - March 7 at 1:04 PM
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 1:04 PM
NeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsNeuroPace Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 7 at 8:04 AM
NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 7 at 3:02 AM
Recap: NeuroPace Q4 EarningsRecap: NeuroPace Q4 Earnings
benzinga.com - March 6 at 5:01 PM
NeuroPace GAAP EPS of -$0.23NeuroPace GAAP EPS of -$0.23
msn.com - March 6 at 5:01 PM
NeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending ConcernsNeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending Concerns
markets.businessinsider.com - March 6 at 5:01 PM
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 MillionNeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
globenewswire.com - March 5 at 4:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Apollo Endosurgery logo

Apollo Endosurgery

NASDAQ:APEN
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
CVRx logo

CVRx

NASDAQ:CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DarioHealth logo

DarioHealth

NASDAQ:DRIO
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
NeuroPace logo

NeuroPace

NASDAQ:NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.